MENU
+Compare
RGEN
Stock ticker: NASDAQ
AS OF
Aug 18, 12:50 PM (EDT)
Price
$124.83
Change
+$0.47 (+0.38%)
Capitalization
7B

RGEN stock forecast, quote, news & analysis

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies... Show more

Industry: #Biotechnology
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RGEN showed earnings on July 29, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for RGEN with price predictions
Aug 15, 2025

RGEN in -2.21% downward trend, sliding for three consecutive days on August 15, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RGEN declined for three days, in of 288 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RGEN moved out of overbought territory on July 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on July 21, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for RGEN entered a downward trend on August 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on RGEN as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RGEN just turned positive on August 13, 2025. Looking at past instances where RGEN's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

RGEN moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.393) is normal, around the industry mean (10.930). RGEN's P/E Ratio (511.111) is considerably higher than the industry average of (62.137). RGEN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.886). RGEN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (10.352) is also within normal values, averaging (39.773).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 11.04B. The market cap for tickers in the group ranges from 246 to 172.16B. ISRG holds the highest valuation in this group at 172.16B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 12%. TRUMF experienced the highest price growth at 21%, while CUPR experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was 26% and the average quarterly volume growth was 46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 65
Price Growth Rating: 60
SMR Rating: 80
Profit Risk Rating: 91
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
1783
Web
https://www.repligen.com